Columbia Brain Imaging Research Suspended
“There could be a patient safety issue, for one, and there could be a scientific validity issue. If you’re exposing people to radiation and getting garbage data, then that becomes an ethical problem.”
“There could be a patient safety issue, for one, and there could be a scientific validity issue. If you’re exposing people to radiation and getting garbage data, then that becomes an ethical problem.”
Physicians for Human Rights is the first group to argue that the presence of medical personnel who monitored the CIA’s use of torture on detainees–e.g., waterboarding, sleep deprivation and other "enhanced" interrogation techniques–rendered these medical professionals complicit in lending support to interrogation practices that were intentionally harmful.
"Did you have permission to use Havasupai blood for your research?" At the heart of this case is a conflict of interests between scientists at powerful institutions that stand to profit from DNA research and powerless members of an underclass.
"OHRP shared your concerns and discussed them with the National Heart Lung and Blood Institute. They appreciated the concerns and have revised the protocol to address them."
Why Has Columbia Expended So Much Effort to Avoid the Conclusion of Patient Harm?
Even worse, FDA officials, in collusion and collaboration with GSK, approved an unethical and exploitative clinical trial—TIDE, which is on-going.
Given multiple prior investigations of Dr. Wakefied’s 1998 paper, why did it take the Lancet editors 12 years to discover a lack of proper IRB approval?
The Alliance for Human Research Protection (AHRP) has recently obtained further information reaffirming our original concerns and raising new ones about the safety and ethics of a government sponsored clinical trial.
AHRP is concerned about the ethics and safety of human subjects in a blood storage experiment ( RECESS) sponsored
by the National Heart Lung and Blood Institute.
The case is so egregious that OHRP officials have taken the rare action of demanding that Columbia University track down the patients involved in the experiment and their families, and acknowledge that they never were informed about the “true nature” of the drug study, the risks they faced or the consequences of their participation.
April 14: the FDA announced that Coast IRB "has agreed to voluntarily halt some aspects of its clinical trial oversight operations due to serious concerns about the company’s ability to protect human subjects participating in clinical trials."
"The strategy of big companies when they are dealing with smaller opponents is to stretch the process, to overwhelm us until we are ready to accept whatever they want to offer."